Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | ACAT2 | Q9BWD1 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17992049 | 0.92 | ENPP2 (0.37) | ENPP2ATXN2CCNT1CDK9ACAT2 | |
| SCHEMBL17992073 | 0.89 | CCNT1 (0.42) | CCNT1CDK9ACAT2PIK3CAPIK3CB | |
| SCHEMBL25664185 | 0.85 | ACAT2 (0.36) | ACAT2PIK3CAPIK3CBMAOBHTR6 | |
| SCHEMBL17757457 | 0.85 | ACAT2 (0.33) | CCNT1CDK9ACAT2CNR1CNR2 | |
| SCHEMBL17757746 | 0.84 | HRH4 (0.42) | CCNT1CDK9ACAT2MAOBHTR6 | |
| SCHEMBL17992047 | 0.83 | BRD4 (0.42) | ACAT2 | |
| SCHEMBL17758095 | 0.83 | CCNT1 (0.33) | CCNT1CDK9ACAT2CNR1 | |
| SCHEMBL17992046 | 0.83 | BRD4 (0.41) | CNR1CNR2 | |
| SCHEMBL17992057 | 0.83 | CHRM2 (0.38) | CNR1CNR2 | |
| SCHEMBL17757475 | 0.82 | ACAT2 (0.43) | ACAT2MAOBHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802956-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN (DE) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | AIFM2, BAD, AIFM1 | ENPP2 347/4885ATXN2 4349/4885CCNT1 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.